Esmat SM, El-Mofty M, Rasheed H, et al. - In cases of vitiligo for which corticosteroids are contraindicated or immune-suppression is unjustified, NB-UVB affords the only well-established vitiligo therapy that can be employed solely. Nonetheless, together with corticosteroids, it not only expedites response but also improves compliance.

• A multicenter, placebo-controlled, randomized, prospective study of 64 patients with active non-segmental vitiligo (vitiligo disease activity ≥2) who were randomly assigned to either NB-UVB and placebo (NB-placebo) or NB-UVB and dexamethasone OMP therapy (NB-OMP) for 6 months.

• The NB-OMP group had earlier control of disease activity but it was comparable in both groups by the end of the study span.

• Both groups showed an impact of disease activity prior to therapy on control of activity.

• Therefore, NB-UVB was identified to be a safe sole treatment option in vitiligo management.

• NB-UVB efficiently allows repigmentation, and represents a comparable stabilizing option to systemic corticosteroids in spite of slightly delayed control.